Showing Results for: “type 1 diabetes”

Data Indicates How Changes to Public Health Recommendation on BPA has Potential to Decrease Diabetes Risk A new study reveals the benefits of reducing exposure to a common chemical for reducing the risk of diabetes. The findings are the first to provide evidence that BPA administration may increase type 2 diabetes risk and were presented as an Oral Presentation - Presidents' Select Abstract as well as a Symposium at the 84 th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Bisphenol A (BPA) is an industrial chemical used to make polycarbonate plastic and epoxy

(NAPS)—Gestational diabetes is something to be concerned about after and not just during pregnancy. Gestational diabetes is diabetes that is found for the first time when a woman is pregnant. If you had gestational diabetes when you were pregnant, you and your child from that pregnancy have a lifelong risk for developing diabetes, a serious disease that can lead to health problems such as heart disease, blindness, kidney disease and amputations. The good news is there are steps you can take to prevent or delay type 2 diabetes and lower that risk for you and your child. Get Tested for Diabetes

Meta-Analysis Compared Rate of Life-Threatening Diabetes Complication Among Children Prior to and During the COVID-19 Pandemic New data presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) revealed the incidence of severe diabetic ketoacidosis (DKA) among children with type 1 diabetes was significantly higher during the pandemic compared to pre-pandemic. DKA is a serious, life-threatening condition that can lead to diabetic coma or even death. While DKA can happen to anyone with diabetes, it is most common among people with type 1 diabetes. DKA is caused by an

RESCUE Advocacy Group to Share Latest Insights on Prevalence and Prevention Strategies A symposium presented by international research group, RESCUE (REducing SuiCide rates amongst individUals with diabEtes) Collaborative Community, will address the ongoing connection between suicide and people with type 1 diabetes, with the goal of highlighting available resources and key takeaways for the field. The symposium comes at a time when adolescents and young adults with type 1 diabetes are 61% more likely to say they feel suicidal than those without diabetes. Suicide and Self-Injury—Unveiling and

The American Diabetes Association ® (ADA) and the European Association for the Study of Diabetes (EASD) announced today their new consensus update on management of hyperglycemia in type 2 diabetes. The update has been prepared by an international committee of experts that include John B. Buse, MD, PhD, (University of North Carolina School of Medicine, Chapel Hill, NC); Melanie J. Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSciat (Leicester Diabetes Centre, Leicester, UK); and their colleagues. It updates the previous 2018 and 2019 consensus reports, and like its predecessors, this new document

Whole Body Digital Twin Technology Enables Personalized Approach to Help Improve Disrupted Metabolism for Individuals with Type 2 Diabetes A new study powered by artificial intelligence (AI), Whole Body Digital Twin, reveals the highest reported rate of remission of type 2 diabetes to date. The findings were presented as a late-breaking poster session at the 82nd Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans, LA. For individuals with type 2 diabetes, remission is defined as sustaining normal blood glucose (blood sugar) levels for at least three months without

For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin, an oral, sodium-glucose co-transporter-2 (SGLT2) inhibitor, has a renal- and cardiovascular-protective effect in reducing the progression of kidney impairment, according to the results of the CREDENCE trial presented today in a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. In the first of several renal outcomes studies of SGLT2s, the landmark Canagliflozin and Renal Events in Diabetes with Established Nephropathy

In an analysis of the AWARD-7 study, people with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD) who took 1.5 mg of dulaglutide once weekly had a reduction of clinical events associated with end-stage kidney disease (ESKD) including dialysis and with a kidney transplant, and a slower rate of kidney function decline compared to people who used insulin or a lower dose of dulaglutide. The study is an abstract titled “Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) Versus Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria

The American Heart Association ® and American Diabetes Association’s ® Know Diabetes by Heart™ initiative reveals new ambassador class during American Diabetes Month ® Seven individuals living with type 2 diabetes and representing a wide range of experiences have been selected as the 2020-21 national ambassadors for Know Diabetes by Heart—a joint effort between the American Heart Association and the American Diabetes Association to combat cardiovascular disease, the leading cause of death for people with type 2 diabetes. Compared to people without diabetes, people living with type 2 diabetes

Veterans Health Administration program combining telemonitoring, self-management and medication support improves HbA1c levels within six months In a project entitled “Implementation of Intensive Telehealth Intervention for Rural Patients with Uncontrolled Diabetes,” researchers revealed improved HbA1c levels among rural patients with poorly-controlled type 2 diabetes who participated in a comprehensive telehealth program. The results were presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions®. The study found a 1.36% reduction in HBA1c levels after